NanoViricides Advances Measles Drug Program as Global Outbreaks Rise
TL;DR
NanoViricides Inc. is advancing NV-387, a potential first-in-class therapeutic for Measles, offering a strategic edge in addressing vaccine failures and rising global cases.
NV-387, NanoViricides' clinical-stage antiviral, is being tested in genetically modified mice to validate its mechanism of mimicking human cells to neutralize Measles virus.
NV-387's development by NanoViricides represents hope for combating Measles outbreaks, aiming to improve global health amidst increasing vaccine challenges and declining immunization rates.
Discover how NanoViricides' NV-387, a drug that cured lethal RSV in animals, is now targeting Measles with a novel approach to virus neutralization.
Found this article helpful?
Share it with your network and spread the knowledge!
NanoViricides, Inc. (NYSE American: NNVC) has taken a significant step forward in addressing the global Measles crisis by initiating animal trials for its clinical-stage antiviral candidate, NV-387. This development comes at a time when Measles outbreaks are surging worldwide, fueled by vaccine failures and decreasing immunization rates. The study utilizes genetically modified mice that express the human CD150/SLAM receptor, essential for viral entry, to assess NV-387's efficacy as potentially the first effective therapeutic for Measles.
The urgency of this research is underscored by recent statistics, with the U.S. reporting over 1,000 cases in 2025 and Europe experiencing a tenfold increase in cases last year. NV-387, which has previously demonstrated success in curing lethal RSV infections in animals, is designed to mimic human cell surfaces, thereby neutralizing viruses by binding and dismantling them. This innovative approach could revolutionize the treatment of Measles, offering hope where traditional vaccine strategies are increasingly challenged.
The implications of NanoViricides' work extend beyond Measles, as NV-387 is also being considered for other respiratory viral infections, including COVID-19 and influenza. The company's progress in advancing NV-387 into Phase II human clinical trials marks a pivotal moment in antiviral therapy, potentially setting a new standard for treating viral infections amidst growing global health threats.
Curated from InvestorBrandNetwork (IBN)
